BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23279038)

  • 1. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
    Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
    BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Schroeck FR; Jacobs BL; Bhayani SB; Nguyen PL; Penson D; Hu J
    Eur Urol; 2017 Nov; 72(5):712-735. PubMed ID: 28366513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
    Amin NP; Sher DJ; Konski AA
    Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service.
    Close A; Robertson C; Rushton S; Shirley M; Vale L; Ramsay C; Pickard R
    Eur Urol; 2013 Sep; 64(3):361-9. PubMed ID: 23498062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.
    Ramsay C; Pickard R; Robertson C; Close A; Vale L; Armstrong N; Barocas DA; Eden CG; Fraser C; Gurung T; Jenkinson D; Jia X; Lam TB; Mowatt G; Neal DE; Robinson MC; Royle J; Rushton SP; Sharma P; Shirley MD; Soomro N
    Health Technol Assess; 2012; 16(41):1-313. PubMed ID: 23127367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
    BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
    Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
    Muralidhar V; Nguyen PL
    Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
    Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
    J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robotic Surgical System for Radical Prostatectomy: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(11):1-172. PubMed ID: 28744334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
    Eldefrawy A; Katkoori D; Abramowitz M; Soloway MS; Manoharan M
    Urol Oncol; 2013 Jul; 31(5):576-80. PubMed ID: 21616691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
    Parikh R; Sher DJ
    Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
    Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
    BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
    J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
    Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
    BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.